Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

FEMY vs ICU: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

FEMY Captures Overall Composite Edge (52.6 HOLD vs 41.7 SELL), While ICU Leads 3–2 on Growth & Valuation Pillars

FEMY Overall Winner 6-Pillar Tally: FEMY 2 – 3 ICU (1 Tie) Matrix Metrics: FEMY 4 – 2 ICU

As of Nov 16, 2026, Femasys Inc. (FEMY) captures the overall head-to-head institutional edge over SeaStar Medical Holding Corporation (ICU) on higher Unified Composite conviction (52.6/100 HOLD vs. 41.7/100 SELL) after splitting the core matrix 4–2 (led by Valuation Multiples, Options & Positioning), while ICU wins 3–2 across the 6-pillar growth and valuation breakdown. FEMY trades at $1.28 (N/M Forward P/E, -763.9% operating margin) versus ICU at $0.85 (N/M Forward P/E, -816.6% operating margin).

  • Growth vs. Quality Trade-Off: FEMY earns the overall head-to-head edge with a stronger Unified Composite Score (52.6/100 HOLD vs. ICU 41.7/100 SELL) and 4.01β · 72% Vol risk profile, whereas ICU leads top-line expansion (+82.0% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: FEMY is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 34.6); meanwhile ICU is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 21.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About FEMY vs ICU
FEMY NASDAQ Head-to-Head Winner
Femasys Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$1.28
-9.86% 1D
Market Cap $11.9M
TTM Revenue $2.3M
Forward P/E N/M
Beta / 30D Vol 4.01β · 72% Vol
Unified Composite Score
52.6 / 100 HOLD
Tech 61.0 Fund 62.0 Flow 50.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -21.5%), weak momentum, RSI 35
RSI-14: 34.6 · SMA20: $1.43 · SMA50: $1.92
ICU NASDAQ
SeaStar Medical Holding Corporation Common Stock
Surgical & Medical Instruments & Apparatus
$0.85
+1.8% 1D
Market Cap $4.5M
TTM Revenue $1.7M
Forward P/E N/M
Beta / 30D Vol 1.35β · 174% Vol
Unified Composite Score
41.7 / 100 SELL
Tech 25.0 Fund 42.0 Flow 50.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -13.3%), weak momentum, RSI 21
RSI-14: 21.1 · SMA20: $2.10 · SMA50: $2.89

6-Pillar Scorecard Institutional Category Breakdown (FEMY 2 – 3 ICU)

Columns: Metric · FEMY · ICU
1. Valuation Multiples FEMY
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 4.9x N/M
2. Growth & Scale ICU
Revenue Growth (YoY) -18.9% +82.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $2.3M $1.7M
Market Cap $11.9M $4.5M
3. Profitability & Quality ICU
Gross Margin 60.9% 92.6%
Operating Margin -763.9% -816.6%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -425.0% -356.9%
4. Balance Sheet & Cash Flow ICU
Cash Generation (TTM) -$19M N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage -$658,045 Net Debt (0.65x D/E) $6.8M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning FEMY
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Instruments & Supplies Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: FEMY (4) vs ICU (2)
Institutional Metric FEMY ICU Criterion Row Edge
Market Capitalization
Scale
$11.9M $4.5M Larger Scale Tie
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-18.9% +82.0% Higher Growth ICU
Operating Margin (TTM)
Profitability
-763.9% -816.6% Higher Margin FEMY
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-425.0% -356.9% Higher ROE ICU
52-Week Range Position
Momentum
17% ($0–$6) 12% ($0–$5) Stronger Trend FEMY
Beta / 30D Volatility
Risk Regime
4.01β · 72% Vol 1.35β · 174% Vol Lower Realized Risk FEMY
Unified Institutional Score
Composite Signal
52.6 / 100 (HOLD) 41.7 / 100 (SELL) Higher Composite FEMY
Trailing 12M Revenue (USD)
Operating Scale
$2.3M $1.7M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
60.9% 92.6% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 4.9x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$19M (-$658,045 Net Debt (0.65x D/E)) N/A ($6.8M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon FEMY +48.15 pp
FEMY: -22.42% · ICU: -70.57%
3M Horizon FEMY +32.63 pp
FEMY: -41.82% · ICU: -74.45%
6M Horizon FEMY +331.47 pp
FEMY: +252.81% · ICU: -78.66%
1Y Horizon ICU +30.72 pp
FEMY: +54.78% · ICU: +85.5%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period FEMY Revenue ICU Revenue FEMY Op. Margin ICU Op. Margin Margin Leader
FY2020 $0M N/A -668.0% N/A FEMY
FY2021 $0M N/A -706.7% N/A FEMY
FY2022 $0M N/A -961.7% N/A FEMY
FY2023 $0M N/A -1353.4% N/A FEMY
FY2024 $0M $0M -1091.8% -13216.3% FEMY
FY2025 $0M $0M -767.0% -986.6% FEMY

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
FEMY UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact FEMY Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ICU BREAKDOWN
133d in phase · OBV DISTRIBUTION
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact ICU Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
FEMY Moat Profile Cyclical / Execution-Driven Positioning
Medical Instruments & Supplies Operator
Competes within the Medical Instruments & Supplies value chain with $11.9M market capitalization and -763.9% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ICU Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $4.5M market capitalization and -816.6% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ FEMY vs ICU Key Questions & Quantitative Answers

As of Nov 16, 2026, Femasys Inc. (FEMY) captures the overall head-to-head institutional edge over SeaStar Medical Holding Corporation (ICU) on higher Unified Composite conviction (52.6/100 HOLD vs. 41.7/100 SELL) after splitting the core matrix 4–2 (led by Valuation Multiples, Options & Positioning), while ICU wins 3–2 across the 6-pillar growth and valuation breakdown. FEMY trades at $1.28 (N/M Forward P/E, -763.9% operating margin) versus ICU at $0.85 (N/M Forward P/E, -816.6% operating margin). Growth vs. Quality Trade-Off: FEMY earns the overall head-to-head edge with a stronger Unified Composite Score (52.6/100 HOLD vs. ICU 41.7/100 SELL) and 4.01β · 72% Vol risk profile, whereas ICU leads top-line expansion (+82.0% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: FEMY is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 34.6); meanwhile ICU is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 21.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ICU leads the Growth & Scale pillar: FEMY posts -18.9% YoY revenue growth and +0.0% YoY earnings growth on $2.3M TTM revenue (60.9% gross margin, -763.9% operating margin), compared with ICU at +82.0% YoY revenue growth and +0.0% YoY earnings growth on $1.7M TTM revenue (92.6% gross margin, -816.6% operating margin). Across the 6-period historical trajectory (FY2020 to FY2025), FEMY cumulative revenue shifted N/A while ICU shifted N/A. In operating R&D and SG&A reinvestment, FEMY deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ICU.

FEMY screens cheaper on headline valuation multiples. FEMY trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 4.9x EV/Revenue (unreported FCF margin), whereas ICU trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against FEMY (-425.0% ROE) versus ICU (-356.9% ROE) capital efficiency.

In options market volatility and institutional positioning, FEMY carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (4.01β · 72% Vol realized risk). By comparison, ICU carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.35β · 174% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.